Tonix Pharmaceuticals Announces Outcome of Interim Analysis of Phase 3 RALLY Study of TNX-102 SL for the Management of Fibromyalgia
Go back to Tonix Pharmaceuticals Announces Outcome of Interim Analysis of Phase 3 RALLY Study of TNX-102 SL for the Management of Fibromyalgia| TONIX PHARM HLDG (NASDAQ: TNXP) | Delayed: 12.83 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $12.83 | 52 Week High | $7.95 | |||
| Open | $12.83 | 52 Week Low | $0.40 | |||
| Day High | $12.83 | P/E | N/A | |||
| Day Low | $12.83 | EPS | $-5.33 | |||
| Volume | 1,242 | |||||

